Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial

BACKGROUND: For synchronous metastatic renal cell carcinoma (RCC), surgical resection of the primary tumor in the presence of distant metastases has been the standard of therapy for select patients followed by systemic therapy. In the era of TKIs two randomized trials, CARMENA and SURTIME, have questioned the role and timing of surgery in these patients, results point towards no surgery or a deferred approach. RATIONALE: The antitumor activity of immune checkpoint blockage (ICB) is more potent than other therapy in mRCC. The deferred cytoreductive nephrectomy approach ensures systemic therapy

Trial Details

NCT ID
NCT03977571
Phase
NA
Sponsor
Niels Fristrup
Status
RECRUITING
Cancer Type
Clear Cell Renal Cell Carcinoma Kidney Cancer
Interventions
  • Cytoreductive nephrectomy
  • Tissue sampling
Locations (sample)
  • Aarhus, Central Region of Denmark, Denmark|56.15674,10.21076
  • Herlev, Denmark|55.72366,12.43998
  • Odense, Denmark|55.39594,10.38831
  • Helsinki, Finland|60.16952,24.93545
  • Tønsberg, Vestfold, Norway|59.26754,10.40762

Key Eligibility Criteria

  • Signed written informed consent obtained prior to any study specific procedures.
  • Patient must be willing and able to comply with the protocol.
  • Core needle biopsy proven metastatic renal cell carcinoma - all histologic subtypes acceptable.
  • Synchronous metastatic renal cell carcinoma with the primary tumor present in the kidney.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Clear Cell Renal Cell Carcinoma Kidney Cancer Trials on Trialify →